Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Panitumumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 20Vectibix

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Vectibix

    Panitumumab

    arrow
    FNCE
    Not Confirmed

    Brand Name : Vectibix

    Japan
    arrow
    FNCE
    Not Confirmed

    Takeda

    Panitumumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 204

    2018 Revenue in Millions : 188

    Growth (%) : 8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Vectibix

    Panitumumab

    arrow
    FNCE
    Not Confirmed

    Brand Name : Vectibix

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Amgen

    Panitumumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 811

    2019 Revenue in Millions : 744

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Vectibix

    Panitumumab

    arrow
    FNCE
    Not Confirmed

    Brand Name : Vectibix

    Japan
    arrow
    FNCE
    Not Confirmed

    Takeda

    Panitumumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 221

    2019 Revenue in Millions : 208

    Growth (%) : 6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Vectibix

    Panitumumab

    arrow
    FNCE
    Not Confirmed

    Brand Name : Vectibix

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Amgen

    Panitumumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 873

    2020 Revenue in Millions : 811

    Growth (%) : 8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Vectibix

    Panitumumab

    arrow
    FNCE
    Not Confirmed

    Brand Name : Vectibix

    Japan
    arrow
    FNCE
    Not Confirmed

    Takeda

    Panitumumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 209

    2020 Revenue in Millions : 212

    Growth (%) : 6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Vectibix

    Panitumumab

    arrow
    FNCE
    Not Confirmed

    Brand Name : Vectibix

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Amgen

    Panitumumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 893

    2021 Revenue in Millions : 873

    Growth (%) : 2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Vectibix

    Panitumumab

    arrow
    FNCE
    Not Confirmed

    Brand Name : Vectibix

    Japan
    arrow
    FNCE
    Not Confirmed

    Takeda

    Panitumumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 196

    2021 Revenue in Millions : 209

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Vectibix

    Panitumumab

    arrow
    FNCE
    Not Confirmed

    Brand Name : Vectibix

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Amgen

    Panitumumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 984

    2022 Revenue in Millions : 893

    Growth (%) : 10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Vectibix

    Panitumumab

    arrow
    FNCE
    Not Confirmed

    Brand Name : Vectibix

    Japan
    arrow
    FNCE
    Not Confirmed

    Takeda

    Panitumumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 179

    2022 Revenue in Millions : 196

    Growth (%) : 3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Vectibix

    Panitumumab

    arrow
    FNCE
    Not Confirmed

    Brand Name : Vectibix

    Japan
    arrow
    FNCE
    Not Confirmed

    Takeda

    Panitumumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2024 Revenue in Millions : 182

    2023 Revenue in Millions : 178

    Growth (%) : 2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF